Market Place
Sourcing Support
Sapience Announces Multiple Presentations At SITC 39th Meeting
08 Oct 2024 //
PR NEWSWIRE
Sapience Enrolls First Patient in Phase 2 Colorectal Cancer Study
01 Oct 2024 //
PR NEWSWIRE
Sapience`s ST101 Shows Positive GBM Data, Biomarkers In ASCO Oral Session
01 Jun 2024 //
PR NEWSWIRE
Sapience St101 Glioblastoma Featured: Phase 2 Clinical Biomarkers Asco
23 May 2024 //
PR NEWSWIRE
Sapience Therapeutics Presents Three Posters at the AACR Annual Meeting 2024
08 Apr 2024 //
PR NEWSWIRE
Sapience Therapeutics to Present Multiple Posters at AACR Annual Meeting 2024
05 Mar 2024 //
PR NEWSWIRE
Sapience Therapeutics Presents ST101 Clinical Data and ST316 Preclinical Data
13 Oct 2023 //
PR NEWSWIRE
Sapience doses first patient in trial of ST316 for solid tumours
14 Jun 2023 //
CLINICAL TRIALS ARENA
Sapience Announces First Patient Dosed in Phase 1-2 Clinical Study of ST316
13 Jun 2023 //
PR NEWSWIRE
Sapience to Present Late-Breaking Data on ST101 and ST316 at AACR
14 Apr 2023 //
PR NEWSWIRE
Sapience Announces Research Poster Presentations on ST101 and ST316
16 Mar 2023 //
PR NEWSWIRE
Sapience Receives IND Clearance from FDA to Proceed with Ph 1-2 Study of ST316
14 Mar 2023 //
PR NEWSWIRE
Sapience Presents Data on the Immune Activating Function of ST101 at(SITC)
10 Nov 2022 //
PRNEWSWIRE
Sapience Announces Presentation on the Immune Activating Function of ST101
12 Oct 2022 //
PRNEWSWIRE
Sapience Therapeutics Awarded SBIR Phase 2 Grant from NCI of the NIH for ST101
04 Oct 2022 //
PRNEWSWIRE
Sapience Tx Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101
08 Aug 2022 //
PRNEWSWIRE
Sapience Therapeutics Announces Expansion of PII Study Arm with ST101
02 Jun 2022 //
PRNEWSWIRE
Peptide biotech gets renewed support from Bristol Myers and others
31 May 2022 //
ENDPTS
Sapience Therapeutics Announces Poster Presentation on ST101 PI Results
12 May 2022 //
PRNEWSWIRE
Sapience Presents Data at AACR 2022 for Targeting Intracellular Interactions
11 Apr 2022 //
PRNEWSWIRE
Sapience Therapeutics Expands Executive Team; Appoints VP, Regulatory Affairs
31 Mar 2022 //
PRNEWSWIRE
Sapience Tx Announces Multiple Poster Presentations at AACR 2022
09 Mar 2022 //
PRNEWSWIRE
Sapience Therapeutics Doses First Patient in Phase 2 Clinical Trial of ST101
06 Jan 2022 //
PRNEWSWIRE
Sapience Therapeutics Announces Multiple Poster Presentations on ST101
29 Oct 2021 //
PRNEWSWIRE
Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI)
12 Oct 2021 //
PRNEWSWIRE
Sapience Enters Into Collaboration with National Cancer Institute (NCI)
27 May 2021 //
PRNEWSWIRE
Sapience Enters Into Collaboration with National Cancer Institute (NCI) ST101
27 May 2021 //
PRNEWSWIRE
Sapience Announces Multiple Posters, Including Late-Breaker, at the American
06 Apr 2021 //
PRNEWSWIRE
Sapience Therapeutics Announces First Patient Dosed with ST101 in Ph 1/2 Study
12 Aug 2020 //
ACCESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.